Results 121 to 130 of about 737 (141)

Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis, 2023
Azvudine (FNC) is a new drug conditionally approved in 2022 for the treatment of coronavirus disease 2019 (COVID-19) in China. However, the exposure level of FNC in COVID-19 patients in clinical practice is still obscure, and there is no liquid chromatography-tandem mass spectrometry (LC-MS/MS) or LC method reported for quantifying the FNC.
Zhijun Liu, Fengying Liang, Shouhong Gao, Xiujing Zhu, Xinhua Song, Wansheng Chen, Xia Tao, Zhipeng Wang, Deduo Xu   +8 more
openaire   +2 more sources

A Retrospective Study on Azvudine in Hospitalized Elderly Patients with COVID-19

Coronaviruses
Background: The ongoing 2019 novel coronavirus pneumonia pandemic continues to pose a serious threat to public health and safety. In response, numerous specific anti-SARS-CoV-2 drugs have been urgently approved for use. Azvudine has been recommended as a priority treatment for COVID-19 patients, but its efficacy and safety in elderly patients remain ...
Ruifang Nie, Ning Hou, Ke Xu, Shan Shen, Shuangshuang Yang   +4 more
openaire   +1 more source

Abstract 6493: Azvudine combined with Doxitinib, a potential therapy for EGFRm+ NSCLC

Cancer Research
Abstract Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is the current standard first-line therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Although Osimertinib significantly improves progression-free survival (PFS), some patients exhibit intrinsic resistance, and nearly all ...
Jianmei Zhang, Shufang Zhang, Yujie Wang, Limin Jia, Ying Li, Pan Li, Feng Luo, Jinfa Du   +7 more
openaire   +1 more source

Azvudine

Reactions Weekly, 2023
openaire   +2 more sources

Real‐world effectiveness of azvudine: Elixir or equivocal answer?

Journal of Medical Virology, 2023
Yuan Gao, Zujin Luo, Zhongjie Hu, Yingmin Ma   +3 more
openaire   +2 more sources

Evaluate clinical effectiveness of Azvudine with data rather than speculation

Journal of Medical Virology, 2023
Guangtong Deng, Daishi Li, Yihuang Liu, Minxue Shen   +3 more
openaire   +2 more sources

Abstract 3866: Azvudine: An emerging immunomodulator in the treatment of cancer and viral infections

Cancer Research
Abstract Azvudine (FNC) is a nucleoside analog that has secured approval from the CDE in China for the treatment of both AIDS and COVID-19. In these contexts, it has showed remarkable efficacy and safety when taken orally. Typically, nucleoside analog drugs function by integrating into DNA and impeding DNA synthesis, evident in drugs ...
Pan Li, Limin Jia, Zhaoyang Wang, Jinfa Du   +3 more
openaire   +1 more source

Azvudine/methylprednisolone

Reactions Weekly, 2023
openaire   +1 more source

Cost-effectiveness of Azvudine for High-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in China

Clinical Therapeutics
This study aimed to evaluate the cost-effectiveness of Azvudine for the treatment of mild-to-moderate coronavirus disease 2019 in high-risk outpatients using real-world data and relevant references.In the decision-tree model, 2 cohorts were organized in a single center to compare the cost-effectiveness between the Azvudine plus symptomatic treatment ...
Hui, Yang, Zhaojian, Wang, Chunping, Wang, Ying, Zhang, Sheng, Han, Zhuoling, An   +5 more
openaire   +2 more sources

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study

EClinicalMedicine, 2023
Yating Dian, Minxue Shen, Furong Zeng
exaly